Buscar
Prelude Therapeutics Inc
PRLDAñadir a la lista de seguimiento
4.600USD
-0.450-8.91%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
366.37MCap. mercado
PérdidaP/E TTM
Más Datos de Prelude Therapeutics Inc Compañía
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
Información de Prelude Therapeutics Inc
Símbolo de cotizaciónPRLD
Nombre de la empresaPrelude Therapeutics Inc
Fecha de salida a bolsaSep 25, 2020
Director ejecutivoVaddi (Krishna)
Número de empleados131
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 25
Dirección175 Innovation Boulevard
CiudadWILMINGTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19805
Teléfono13024671280
Sitio Webhttps://preludetx.com/
Símbolo de cotizaciónPRLD
Fecha de salida a bolsaSep 25, 2020
Director ejecutivoVaddi (Krishna)
Ejecutivos de Prelude Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
--
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+21.87%
Dr. Peggy A. Scherle, Ph.D.
Dr. Peggy A. Scherle, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
190.69K
+2.62%
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Independent Director
Independent Director
--
--
Mr. Martin Babler
Mr. Martin Babler
Independent Director
Independent Director
--
--
Mr. Bryant D. Lim, J.D.
Mr. Bryant D. Lim, J.D.
Chief Financial Officer, Chief Legal Officer, Corporate Secretary
Chief Financial Officer, Chief Legal Officer, Corporate Secretary
--
--
Dr. Paul Scherer, M.D.
Dr. Paul Scherer, M.D.
Independent Director
Independent Director
--
--
Ms. Katina Dorton
Ms. Katina Dorton
Director
Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
--
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+21.87%
Dr. Peggy A. Scherle, Ph.D.
Dr. Peggy A. Scherle, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
190.69K
+2.62%
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Prelude Therapeutics Inc?
Los cinco principales accionistas de Prelude Therapeutics Inc son: Dr. Krishna (Kris) Vaddi, Ph.D.
¿Cuántas instituciones poseen acciones de Prelude Therapeutics Inc (PRLD)?
A fecha de 2026Q1, 149 instituciones poseen acciones de Prelude Therapeutics Inc, con un valor de mercado combinado de aproximadamente 30.05M, lo que representa el 57.50% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -7756404.00.